Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018) (DRIVE-FORWARD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02275780
Recruitment Status : Active, not recruiting
First Posted : October 27, 2014
Results First Posted : October 23, 2018
Last Update Posted : August 6, 2020
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Tracking Information
First Submitted Date  ICMJE October 23, 2014
First Posted Date  ICMJE October 27, 2014
Results First Submitted Date  ICMJE September 28, 2018
Results First Posted Date  ICMJE October 23, 2018
Last Update Posted Date August 6, 2020
Actual Study Start Date  ICMJE December 1, 2014
Actual Primary Completion Date September 29, 2016   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: September 28, 2018)
Percentage of Participants Achieving Plasma HIV-1 RNA <50 Copies/mL at Week 48 [ Time Frame: Week 48 ]
The percentage of participants in each arm achieving HIV-1 RNA levels <50 copies/mL at Week 48 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach and all missing data were considered treatment failures, regardless of the reason.
Original Primary Outcome Measures  ICMJE
 (submitted: October 23, 2014)
Percentage of participants achieving HIV-1 RNA <40 copies/mL at Week 48 [ Time Frame: Week 48 ]
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: September 28, 2018)
  • Percentage of Participants Achieving Plasma HIV-1 RNA <50 Copies/mL at Week 96 [ Time Frame: Week 96 ]
    The percentage of participants in each arm achieving HIV-1 RNA levels <50 copies/mL at Week 96 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach and all missing data were considered treatment failures, regardless of the reason.
  • Change From Baseline in Mean CD4+ T-cell Count at Week 48 [ Time Frame: Baseline and Week 48 ]
    CD4+ T-cell counts were quantified by a central laboratory using a commercially available assay.
  • Change From Baseline in Mean CD4+ T-cell Count at Week 96 [ Time Frame: Baseline and Week 96 ]
    CD4+ T-cell counts were quantified by a central laboratory using a commercially available assay.
  • Mean Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 48 [ Time Frame: Baseline and Week 48 ]
    Serum LDL-C was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The Last Observation Carry Forward (LOCF) approach was applied for missing data or data collected after modifying lipid-lowering therapy.
  • Mean Change From Baseline in Fasting Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 48 [ Time Frame: Baseline and Week 48 ]
    Serum non-HDL-C was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.
  • Mean Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Week 48 [ Time Frame: Baseline and Week 48 ]
    Serum HDL-C was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.
  • Mean Change From Baseline in Fasting Total Cholesterol at Week 48 [ Time Frame: Baseline and Week 48 ]
    Serum total cholesterol was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.
  • Mean Change From Baseline in Fasting Triglyceride at Week 48 [ Time Frame: Baseline and Week 48 ]
    Serum triglyceride was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.
  • Percentage of Participants With Any Adverse Event [ Time Frame: Up to 98 weeks ]
    An adverse event (AE) is defined as any untoward medical occurrence in a study participant and which does not necessarily have to have a causal relationship to treatment. An adverse event can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the study treatment or protocol-specified procedure, whether or not considered related to study treatment or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study treatment is also an AE. The percentage of participants with any AE was assessed.
  • Percentage of Participants With Any Serious Adverse Event [ Time Frame: Up to 98 weeks ]
    A serious adverse event is an AE that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is a cancer, is associated with an overdose, or is another important medical event. The percentage of participants with any SAE was assessed.
  • Percentage of Participants With Any Drug-related Adverse Event [ Time Frame: Up to 98 weeks ]
    The investigator was to determine if an AE had a reasonable possibility of a relationship to the study drug. The percentage of participants with any drug-related AE was assessed.
  • Percentage of Participants With Any Drug-related Serious Adverse Event [ Time Frame: Up to 98 weeks ]
    The percentage of participants with any drug-related SAE was assessed.
  • Percentage of Participants Who Discontinued Study Treatment Due to an Adverse Event [ Time Frame: Up to 96 weeks ]
    The percentage of participants who discontinued study treatment due to an AE was assessed.
  • Percentage of Participants Achieving Plasma HIV-1 RNA <40 Copies/mL at Week 48 [ Time Frame: Week 48 ]
    The percentage of participants in each arm achieving HIV-1 RNA levels <40 copies/mL at Week 48 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach and all missing data were considered treatment failures, regardless of the reason.
  • Percentage of Participants Achieving Plasma HIV-1 RNA <40 Copies/mL at Week 96 [ Time Frame: Week 96 ]
    The percentage of participants in each arm achieving HIV-1 RNA levels <40 copies/mL at Week 96 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach and all missing data were considered treatment failures, regardless of the reason.
Original Secondary Outcome Measures  ICMJE
 (submitted: October 23, 2014)
  • Percentage of participants achieving HIV-1 RNA <40 copies/mL at Week 96 [ Time Frame: Week 96 ]
  • Change from baseline in cluster of differentiation 4 (CD4) cell counts at Week 48 [ Time Frame: Baseline and Week 48 ]
  • Change from baseline in CD4 cell counts at Week 96 [ Time Frame: Baseline and Week 96 ]
  • Change from baseline in fasting low density lipoprotein cholesterol (LDL-C) at Week 48 [ Time Frame: Baseline and Week 48 ]
  • Change from baseline in fasting non-high density lipoprotein cholesterol (non-HDL-C) at Week 48 [ Time Frame: Baseline and Week 48 ]
  • Change from baseline in fasting high density lipoprotein cholesterol (HDL-C) at Week 48 [ Time Frame: Baseline and Week 48 ]
  • Change from baseline in fasting total cholesterol at Week 48 [ Time Frame: Baseline and Week 48 ]
  • Change from baseline in fasting triglycerides at Week 48 [ Time Frame: Baseline and Week 48 ]
  • Percentage of participants with any adverse event (AE) [ Time Frame: Up to 14 day post study (up to 98 weeks) ]
  • Percentage of participants with any serious adverse event (SAE) [ Time Frame: Up to 14 day post study (up to 98 weeks) ]
  • Percentage of participants with any drug-related AE [ Time Frame: Up to 14 day post study (up to 98 weeks) ]
  • Percentage of participants with any SAE and drug-related AE [ Time Frame: Up to 14 day post study (up to 98 weeks) ]
  • Percentage of participants who discontinued treatment due to an AE [ Time Frame: Up to 96 weeks ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)
Official Title  ICMJE A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg Once Daily Plus Ritonavir 100 mg Once Daily, Each in Combination With TRUVADA™ or EPZICOM™/KIVEXA™, in Treatment-Naïve HIV-1 Infected Subjects
Brief Summary To establish a new treatment option for treatment-naïve participants with HIV-1, the efficacy and safety of doravirine will be determined relative to a protease inhibitor (PI). Participants will receive double-blind treatment during the 96-week Base Study. Eligible participants in either of the Base Study groups will continue to receive the doravirine-containing regimen open label for an additional 96 weeks in the Study Extension 1. Eligible participants who are deriving benefit will continue in Study Extension 2 to receive the doravirine-containing regimen open label until doravirine becomes locally available or for an additional 96 weeks, whichever comes first. The primary hypothesis is that doravirine 100 mg once a day (q.d.) is non-inferior to darunavir/ritonavir (800 mg/100 mg) q.d., each in combination with TRUVADA™ or EPZICOM™/KIVEXA™, as assessed by the proportion of participants with HIV-1 ribonucleic acid (RNA) <50 copies/mL at Week 48. If non-inferiority is established, then the superiority of doravirine 100 mg q.d. compared to darunavir/ ritonavir (800 mg/100 mg) q.d. will be assessed.
Detailed Description Participants in Australia, Russia, and South Africa who are deriving benefit from MK-1439A are also eligible to continue receiving study drug during Study Extension 3, which will last for 2 years or until drug is available locally, whichever comes first.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE HIV-1
Intervention  ICMJE
  • Drug: Doravirine
    Doravirine 100 mg tablet administered p.o., q.d.
  • Drug: Darunavir
    Darunavir 800 mg tablet administered p.o., q.d.
  • Drug: Ritonavir
    Ritonavir 100 mg tablet administered p.o., q.d.
  • Drug: TRUVADA™ or EPZICOM™/KIVEXA™
    The investigator selects either TRUVADA™, a tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate, p.o., q.d., or EPZICOM™/KIVEXA™, a tablet containing 600 mg abacavir sulfate and 300 mg lamivudine, p.o., q.d.
Study Arms  ICMJE
  • Experimental: Doravirine 100 mg
    Double-blind Doravirine 100 mg administered orally (p.o.) once daily (q.d.) + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study. Eligible participants may continue in Study Extension 1 with open-label Doravirine 100 mg administered p.o., q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for an additional 96 weeks. Eligible participants may continue to receive the same treatment regimen in Study Extension 2 until doravirine becomes locally available, or for an additional 96 weeks, whichever comes first.
    Interventions:
    • Drug: Doravirine
    • Drug: TRUVADA™ or EPZICOM™/KIVEXA™
  • Active Comparator: Darunavir 800 mg and Ritonavir 100 mg
    Double-blind Darunavir 800 mg and Ritonavir 100 mg administered p.o., q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for 96 weeks. Eligible participants may continue in Study Extension 1 with open-label Doravirine 100 mg administered p.o., q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for an additional 96 weeks. Eligible participants may continue to receive the same treatment regimen in Study Extension 2 until doravirine becomes locally available, or for an additional 96 weeks, whichever comes first.
    Interventions:
    • Drug: Doravirine
    • Drug: Darunavir
    • Drug: Ritonavir
    • Drug: TRUVADA™ or EPZICOM™/KIVEXA™
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: May 8, 2018)
769
Original Estimated Enrollment  ICMJE
 (submitted: October 23, 2014)
680
Estimated Study Completion Date  ICMJE May 24, 2021
Actual Primary Completion Date September 29, 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Is HIV-1 positive and has HIV treatment indicated based on physician assessment.
  • Has received no (0 days of) antiretroviral therapy (ART), including investigational antiretroviral agents.
  • Is considered clinically stable with no signs or symptoms of active infection for at least 2 weeks prior to the start of treatment.
  • Female is highly unlikely to become pregnant, or male is highly unlikely to impregnate a partner because they are not of reproductive potential, or agree to practice abstinence or use acceptable contraception for up to 14 days after the last dose of study drug.
  • Eligibility for the Study Extension 1 at the Week 96 visit: 1) completed the Week 96 visit, 2) derived benefit from participation through Week 96 in the opinion of the investigator, 3) is a clinically-appropriate candidate for an additional 96 weeks of treatment with the Study Extension regimen.
  • Eligibility for the Study Extension 2 at the Week 192 visit: 1) completed the Week 192 visit, 2) derived benefit from participation through Week 192 in the opinion of the investigator, 3) is a clinically-appropriate candidate for 96 weeks of treatment with the Study Extension regimen.

Exclusion Criteria:

  • Uses or has had a recent history of using recreational or illicit drugs.
  • Has been treated for a viral infection other than HIV-1, such as hepatitis B, with an agent that is active against HIV-1.
  • Has documented or known resistance to study drugs including doravirine, darunavir, ritonavir, emtricitabine, tenofovir, abacavir and/or lamivudine.
  • Has participated in a study with an investigational compound/device within the prior month, or anticipates doing so during this study.
  • Has used systemic immunosuppressive therapy or immune modulators within the prior 30 days, or anticipates doing so during this study.
  • Has significant hypersensitivity or other contraindication to any of the components of the study drugs.
  • Has a current (active) diagnosis of acute hepatitis due to any cause.
  • Is pregnant, breastfeeding or expecting to conceive at any time during the study.
  • Female who expects to donate eggs, or male who expects to donate sperm at any time during the study.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries Australia,   Austria,   Canada,   Chile,   Denmark,   France,   Germany,   Italy,   Puerto Rico,   Romania,   Russian Federation,   South Africa,   Spain,   United Kingdom,   United States
 
Administrative Information
NCT Number  ICMJE NCT02275780
Other Study ID Numbers  ICMJE 1439-018
2014-001127-69 ( EudraCT Number )
MK-1439-018 ( Other Identifier: Merck Protocol Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
URL: http://engagezone.msd.com/ds_documentation.php
Responsible Party Merck Sharp & Dohme Corp.
Study Sponsor  ICMJE Merck Sharp & Dohme Corp.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Medical Director Merck Sharp & Dohme Corp.
PRS Account Merck Sharp & Dohme Corp.
Verification Date July 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP